William Boothe, MD
Dermatology · Lubbock, TXNPI 1649711904
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Amgen at 33.8% of the total. Reporting peaked in 2021 at $1,409 and has fallen 88.0% since, to $168 in 2025. That places this record below the midpoint for dermatology clinicians in TX, where the typical reported total is $4,085.
Across 120 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$437
- LEO Pharma Inc.$318
- Sun Pharmaceutical Industries Inc.$288
- AbbVie$277
- Regeneron Healthcare Solutions, Inc.$246
- plus $545 from 15 others
What the payments were for
- Food & beverage$3,188100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $1,077 |
| Lilly USA, LLC | 14 | $437 |
| LEO Pharma Inc. | 13 | $318 |
| Sun Pharmaceutical Industries Inc. | 8 | $288 |
| AbbVie | 18 | $277 |
| Regeneron Healthcare Solutions, Inc. | 11 | $246 |
| Bristol Myers Squibb | 5 | $107 |
| Johnson & Johnson | 6 | $98 |
| Kerecis Limited | 1 | $84 |
| Krystal Biotech Inc | 1 | $29 |
| Pfizer | 1 | $28 |
| Biofrontera Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 2 | $25 |
| Organon | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Novartis | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Sanofi | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Galderma Laboratories, L.p. | 1 | $11 |
How this compares
$3,188 in reported general payments places this provider in the 45th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 18 | $70,216 |
| Clobetasol Propionate | 191 | $6,162 |
| Fluorouracil | 87 | $5,621 |
| Doxycycline Monohydrate | 88 | $2,857 |
| Triamcinolone Acetonide | 144 | $2,167 |
| Ketoconazole | 131 | $2,042 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 25 | $1,555 |
| Econazole Nitrate | 22 | $1,283 |
| Tacrolimus | 16 | $1,233 |
| Metronidazole | 24 | $1,173 |
| Hydrocortisone | 82 | $853 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 19 | $840 |
| ValacyclovirValacyclovir Hcl | 19 | $831 |
| Nystatin | 35 | $662 |
| Minoxidil | 44 | $608 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Lubbock
- Michelle TarboxLubbock$177K
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- Daniel CarrascoAustin$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.